Monday, December 24, 2018 11:52:37 PM
- The applications of CBD are numerous. As one example Epidiolex (a purified form of CBD) is FDA approved for treatment of seizures associated with Dravets and Lennox-Gastault syndromes.
- Despite the promise of CBD, it is important to avoid some pitfalls, as illustrated by Charlottes Web, a CBD supplier with established market share receiving a warning letter from FDA for product claims: https://www.fda.gov/newsevents/publichealthfocus/ucm484109.htm
- SRCO appears to be approaching it’s CBD as an organically produced ‘pharmaceutical grade’ product which should realize the market potential by providing the concentration and other attributes that the CBD should have.
- With some of the other developments in the federal de facto legalization of hemp in the recently passed farm bill (see my previous post), it appears that SRCO is well positioned in a promising sector
Jacob J. Rosenblum on what every lawyer knows.
“If the facts are against you, hammer the law. If the law is against you, hammer the facts. If the fact and the law are against you, hammer opposing counsel."
Recent SRCO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:21:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:14:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:06:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 12:57:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 10:15:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/20/2023 09:30:37 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 12/15/2023 10:00:31 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 09/26/2023 09:08:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/19/2023 08:45:34 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/18/2023 10:02:57 AM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 07/31/2023 08:30:09 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM